Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers

Open access

Published version of a preprint

Abstract

Circulating proteins can reveal key pathways to cancer and identify therapeutic targets for cancer prevention. We investigate 2,074 circulating proteins and risk of nine common cancers (bladder, breast, endometrium, head and neck, lung, ovary, pancreas, kidney, and malignant non-melanoma) using cis protein Mendelian randomisation and colocalization. We conduct additional analyses to identify adverse side-effects of altering risk proteins and map cancer risk proteins to drug targets. Here we find 40 proteins associated with common cancers, such as PLAUR and risk of breast cancer [odds ratio per standard deviation increment: 2.27, 1.88-2.74], and with high-mortality cancers, such as CTRB1 and pancreatic cancer [0.79, 0.73-0.85]. We also identify potential adverse effects of protein-altering interventions to reduce cancer risk, such as hypertension. Additionally, we report 18 proteins associated with cancer risk that map to existing drugs and 15 that are not currently under clinical investigation. In sum, we identify protein-cancer links that improve our understanding of cancer aetiology. We also demonstrate that the wider consequence of any protein-altering intervention on well-being and morbidity is required to interpret any utility of proteins as potential future targets for therapeutic prevention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-46834-3

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Manhattan Plot for the association of genetically predicted protein concentrations with cancer risk. Association of genetically predicted protein concentrations with cancer risk estimated using Wald ratios presented as a Manhattan plot where position is given by cis-pQTL coordinate with a selection of cancer risk associations additionally labelled for their association with cancer risk and colocalization probability (PP4). Top result for each cancer endpoint provided. All tests are two-sided. Points highlighted as filled-in are those with PP4 > 0.7 with point size reflecting PP4 magnitude, which can vary between 0 and 1. Risk associations with MR p > 0.05 were not subject to colocalization analyses. Results labelled are those passing correction for multiple testing for the number of proteins analysed in this study per-cancer.
Fig. 1 Manhattan Plot for the association of genetically predicted protein concentrations with cancer risk. Association of genetically predicted protein concentrations with cancer risk estimated using Wald ratios presented as a Manhattan plot where position is given by cis-pQTL coordinate with a selection of cancer risk associations additionally labelled for their association with cancer risk and colocalization probability (PP4). Top result for each cancer endpoint provided. All tests are two-sided. Points highlighted as filled-in are those with PP4 > 0.7 with point size reflecting PP4 magnitude, which can vary between 0 and 1. Risk associations with MR p > 0.05 were not subject to colocalization analyses. Results labelled are those passing correction for multiple testing for the number of proteins analysed in this study per-cancer.CC BY · PubMed Central
Fig. 2 Forrest plot for the associations of 40 protein and cancer risk and pan-cancer risk forrest plots for PLAUR and CTRB1. Proteins associated with cancer risk (A) after correction for multiple testing for the number of proteins analysed in this study per-cancer. Odds ratio estimates are estimated using Wald ratios scaled per standard deviation increment in relative circulating protein concentrations. Confidence intervals (95% CI) are derived using the standard Wald ratio formula and reflect the precision of the cis-pQTL estimate in cancer GWAS scaled by the beta for the cis-pQTL association with protein concentrations. Sample sizes for cancer GWAS can be found in methods. Association of higher PLAUR with cancer risk (B) coloured by the colocalization probability (PP4), where MR Wald p < 0.05. Association for higher CTRB1 with cancer risk presented to demonstrate pancreas-specific association (C) with colour scheme as described above. All tests are two-sided.
Fig. 2 Forrest plot for the associations of 40 protein and cancer risk and pan-cancer risk forrest plots for PLAUR and CTRB1. Proteins associated with cancer risk (A) after correction for multiple testing for the number of proteins analysed in this study per-cancer. Odds ratio estimates are estimated using Wald ratios scaled per standard deviation increment in relative circulating protein concentrations. Confidence intervals (95% CI) are derived using the standard Wald ratio formula and reflect the precision of the cis-pQTL estimate in cancer GWAS scaled by the beta for the cis-pQTL association with protein concentrations. Sample sizes for cancer GWAS can be found in methods. Association of higher PLAUR with cancer risk (B) coloured by the colocalization probability (PP4), where MR Wald p < 0.05. Association for higher CTRB1 with cancer risk presented to demonstrate pancreas-specific association (C) with colour scheme as described above. All tests are two-sided.CC BY · PubMed Central
Fig. 3 Potential consequences of genetically-predicted protein altering interventions as explemplified using FGFR3 and PDXK. Potential consequences, presented as beta coefficients and confidence intervals (95% CI) of a protein-lowering intervention for two emblematic cancer risk proteins, FGFR3 and PDXK, that associated with higher risk of bladder and breast cancer, respectively, estimated using Wald ratios for traits where cis-pQTL had a p-value for association passing correction for multiple testing in main analyses. For reference, the predicted effect of lowering each protein by 1 SD is present for cancer risk at the top (italics and bold). Below these estimates we present the predicted effect of protein-lowering where colocalization and MR analyses suggest an aetiological link with other traits. Colocalization probability (PP4) is also presented for each trait. All tests are two-sided. Box colour indicates whether a predicted consequence may be beneficial (blue), harmful (red) or have uncertain consequence (grey) on health. Box size is proportionate to absolute beta from MR analyses while box opacity is proportionate to precision of this MR estimate.
Fig. 3 Potential consequences of genetically-predicted protein altering interventions as explemplified using FGFR3 and PDXK. Potential consequences, presented as beta coefficients and confidence intervals (95% CI) of a protein-lowering intervention for two emblematic cancer risk proteins, FGFR3 and PDXK, that associated with higher risk of bladder and breast cancer, respectively, estimated using Wald ratios for traits where cis-pQTL had a p-value for association passing correction for multiple testing in main analyses. For reference, the predicted effect of lowering each protein by 1 SD is present for cancer risk at the top (italics and bold). Below these estimates we present the predicted effect of protein-lowering where colocalization and MR analyses suggest an aetiological link with other traits. Colocalization probability (PP4) is also presented for each trait. All tests are two-sided. Box colour indicates whether a predicted consequence may be beneficial (blue), harmful (red) or have uncertain consequence (grey) on health. Box size is proportionate to absolute beta from MR analyses while box opacity is proportionate to precision of this MR estimate.CC BY · PubMed Central
Fig. 4 Stacked bar plot that depicts identified proteins associated with cancer by their current highest level of therapeutic investigation, which additionally has colours that stratified results by cancer site. Figure displays a stacked bar chart, coloured by cancer endpoint for protein in question, mapping of cancer-risk proteins to currently available information on clinical/pharmaceutical investigations. These include cancer-risk proteins that are the target of a currently launched drug, under investigation at Phase I or II, under preclinical or biological testing, and those not known to be under current investigation.
Fig. 4 Stacked bar plot that depicts identified proteins associated with cancer by their current highest level of therapeutic investigation, which additionally has colours that stratified results by cancer site. Figure displays a stacked bar chart, coloured by cancer endpoint for protein in question, mapping of cancer-risk proteins to currently available information on clinical/pharmaceutical investigations. These include cancer-risk proteins that are the target of a currently launched drug, under investigation at Phase I or II, under preclinical or biological testing, and those not known to be under current investigation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 33

Metadata

Authors
Smith-Byrne, K., Hedman, Å., Dimitriou, M., Desai, T., Sokolov, A. V., Schioth, H. B., Koprulu, M., Pietzner, M., Langenberg, C., Atkins, J., Penha, R. C., McKay, J., Brennan, P., Zhou, S., Richards, B. J., Yarmolinsky, J., Martin, R. M., Borlido, J., Mu, X. J., Butterworth, A., Shen, X., Wilson, J., Assimes, T. L., Hung, R. J., Amos, C., Purdue, M., Rothman, N., Chanock, S., Travis, R. C., Johansson, M., & Mälarstig, A.
Affiliations
  • University of Oxford (GB)
  • Karolinska Institutet (SE)
  • Uppsala University (SE)
  • University of Cambridge (GB)
  • Queen Mary University of London (GB)
  • Centre international de recherche sur le cancer (FR)
  • McGill University (CA)
  • University of Bristol (GB)
  • Pfizer (United States) (US)
  • MRC Human Genetics Unit (GB)
  • Stanford University (US)
  • University of Toronto (CA)
  • Baylor College of Medicine (US)
  • National Cancer Institute (US)
Corresponding author
Smith-Byrne, Karl
Venue
Nature Communications
Published
2024-04-29
Volume
15
Issue
1
Pages
3621-3621
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4396219359
Cited by
33
References
63
Citations by year
2026: 10 · 2025: 19 · 2024: 4
FWCI
8.73
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Explore Bristol Research (publishedVersion, cc-by)
  • Uppsala University Publications (Uppsala University) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by)
  • Bristol Research (University of Bristol) (submittedVersion, cc-by)
Funders
Cancer Research UK (C8221/A29017)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Keywords
circulating proteins, cancer risk, therapeutic target, cancer prevention, bladder cancer, breast cancer, pancreatic cancer, kidney cancer, non-melanoma skin cancer, head and neck cancer, endometrial cancer, lung cancer, hypertension, adverse effects, PLAUR
MeSH terms
Blood Proteins, Female, Humans, Male, Neoplasms, Risk Factors, Biomarkers, Tumor, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers. https://app.cochat.ai/papers/10.1038/s41467-024-46834-3
The paper
Smith-Byrne, K., Hedman, Å., Dimitriou, M., Desai, T., Sokolov, A. V., Schioth, H. B., Koprulu, M., Pietzner, M., Langenberg, C., Atkins, J., Penha, R. C., McKay, J., Brennan, P., Zhou, S., Richards, B. J., Yarmolinsky, J., Martin, R. M., Borlido, J., Mu, X. J., . . . Mälarstig, A. (2024). Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers. Nature Communications. https://doi.org/10.1038/s41467-024-46834-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.